Département A: Research in Drug Development (RD3)

Unit 1: Microbiology, Bioorganic and Macromolecular Chemistry (MC)

RESEARCH ACTIVITIES

His main research interests focus on the design and synthesis of metal complexes and organic molecules having potential therapeutic applications against cancer, inflammation and diseases of the central nervous system. He is especially interested in the development of cytotoxic metal complexes, the study of the relationship between their chirality and their bioactivity, and the biological effects on cancer cells using spectroscopic methods.

TOP 10 RECENT ARTICLES:

1.

Synthesis of 15N-labeled vicinal diamines through N-activated chiral aziridines: tools for the NMR study of platinum-based anticancer compounds. Berger, G.; Gelbcke, M.; Cauët, E.; Luhmer, M.; Nève, J.; Dufrasne, F.Tet. Lett.,2013, 54(6), 545-548.Impact factor : 2,7.

2.

Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors Soubhye, J.; Aldib, I.; Elfving, B.; Gelbcke, M.; Furtmuller, P.G.; Podrecca, M.; Conotte, R.; Colet, J.-M.; Rousseau, A.; Reye, F.; Sarakbi, A.; Vanhaeverbeek, M.; Kauffmann, J.-M.; Obinger, C.; Neve, J.; Prevost, M.; Zouaoui Boudjeltia, K.; Dufrasne, F.; Van Antwerpen, P.J. Med. Chem., 2013, 56(10), 3943-3958. Impact factor : 4,8.

3.

Structure–Activity Relationship Analysis of Bufadienolide-Induced in Vitro Growth Inhibitory Effects on Mouse and Human Cancer Cells Moreno Y. Banuls, L.; Urban, E.; Gelbcke, M.; Dufrasne, F.; Kopp, B.; Kiss, R.; Zehl, M.J. Nat. Prod., 2013, 76 (6), 1078–1084. Impact factor : 3,3.

4.

Remifentanil anti-apoptotic Effect on the Immature Mouse Brain: an ex vivo study Tourrel, F.; Kwetieu de Lendeu, P.; Abily-Donval, L.; Chollat, C.; Marret, S.; Dufrasne, F.; Compagnon, P.; Ramdani,Y.; Dureuil, B.; Laudenbach, V.; Gonzalez, B.J.; Jégou, S.Anesth. Analg., 2014, 118(5), 1041-1051.Impact factor : 2,2.

5.

Hybrid Molecules Inhibiting Myeloperoxidase Activity and Serotonin Reuptake: A Possible New Approach of Major Depressive Disorders with Inflammatory Syndrome.Soubhye,J.; Aldib, I.; Prévost, M.; Elfving, B.; Gelbcke, M.; Podrecca, M.; Conotte, R.; Colet, J.-M.; Furtmüller, P.G.; Delporte, C.; Rousseau, A.; Vanhaeverbeek, M.; Nève, J.; Obinger, C.; Zouaoui-Boudjeltia, K.; Van Antwerpen, P.; Dufrasne, F.J. Pharm. Pharmacol., 2014, 66(8), 1122-1132. Impact factor : 2,1.

6.

Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery.Berger, G.; Leclercqz, H.; Derenne, A.; Gelbcke, M.; Goormaghtigh, E.; Neve, J.; Mathieu, V.; Dufrasne, F.Bioorg. Med. Chem., 2014, 22(13), 3527-3536.Impact factor : 2,9.

7.

Insights into the structure-​activity relationships of chiral 1,​2-​diaminophenylalkane platinum(II) anticancer derivatives. Berger, G.; Fusaro, L.; Luhmer, M.; Czapla-Masztafiak, J.; Lipiec, E.; Szlachetko, J.; Kayser, Y.; Fernandes, D. L. A.; Sa, J.; Dufrasne, F.; Bombard, S.J. Biol. Inorg. Chem., 2015, 20(5), 841-853. Impact Factor : 4,6.

8.

Type 2 17-b Hydroxysteroid Dehydrogenase as a Novel Target for Treatment of Osteoporosis. Soubhye, J. ; Chikh Alard, I. ; Van Antwerpen, P. ; Dufrasne, F.Future Med. Chem., 2015, 7(11), 1431-1456. Impact Factor : 3,7.

9.

Resonant X-ray emission spectroscopy of platinum(II) anticancer complexes. Sa, J.; Czapla-Masztafiak, J.; Lipiec, E.; Kayser, Y.; Fernandes, D.L.A. ; Dufrasne, F. ; Berger, G.Analyst, 2016, 141, 1226-1232.Impact Factor : 4,1.

10.

Myeloperoxidase as a Target for Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors Soubhy, J.; Aldib, I. ; Delporte, C.; Prevost, M.; Dufrasne, F.; Van Antwerpen, P.Curr. Med. Chem., 2016, in press. Impact Factor : 3,9.

François Dufrasne

François DUFRASNE

Faculté de Pharmacie

tel 02 650 5235,

Campus de la Plaine

ULB CP205/05, boulevard du Triomphe, 1050 Bruxelles

Career

Lecturer at the Faculty of Medicine and Pharmacy of the University of Mons (Belgium) (2007-).

Lecturer at the Faculty of Medicine (ULB) for the Pharmed courses (2007-).

Lecturer at the Faculty of Pharmacy of (ULB) (2006-).

Assistant-professor at the Faculty of Pharmacy (ULB) (2002-2006)

Assistant in the Laboratory of Organic Pharmaceutical Chemistry (Institute of Pharmacy, ULB) (1996-2002) .

PhD in pharmaceutical sciences (Title: “Conception and synthesis of new stereoselective organic ligands of platinum(II)”), Institude of Pharmacy (ULB) (1996-2002).

Diplome d’étude approfondie en sciences de la santé” at the Institute of Pharmacy (ULB) (2001).

Pharmacist in (1990-1996) with “grande distinction” at the Institute of Pharmacy of the Université Libre de Bruxelles (ULB, Belgium).